

Glenmark Pharmaceuticals Limited

Statement of unaudited financial results for the quarter ended 30 June, 2019

(Rs. In Millions)

Particulars [Refer notes below]	Standalone (Ind AS)				Consolidated (Ind AS)			
	Quarter ended 30/06/2019 (Unaudited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 30/06/2018 (Unaudited)	Year ended 31/03/2019 (Audited)	Quarter ended 30/06/2019 (Unaudited)	Quarter ended 31/03/2019 (Audited)	Quarter ended 30/06/2018 (Unaudited)	Year ended 31/03/2019 (Audited)
I Revenue from operations								
(a) Net sales	14,552.33	15,307.63	13,606.68	61,311.40	22,836.04	25,260.82	21,293.66	97,050.84
(b) Other operating income	435.60	565.16	451.69	1,737.27	392.75	373.92	362.51	1,603.84
Total revenue from operations	14,987.93	15,872.79	14,058.37	63,048.67	23,228.79	25,634.74	21,656.17	98,654.68
II Other income	685.41	1,683.89	1,655.64	4,756.14	16.69	390.57	1,382.16	2,081.37
III Total income (I + II)	15,673.34	17,556.68	15,714.01	67,804.81	23,245.48	26,025.31	23,038.33	100,736.05
IV Expenses								
(a) Cost of materials consumed	5,193.73	2,548.89	4,084.98	15,858.51	6,086.05	6,144.64	4,951.83	24,447.12
(b) Purchase of stock-in-trade	966.13	476.85	746.72	3,012.95	2,587.00	1,718.19	2,452.52	9,762.98
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(92.84)	3,168.80	440.08	4,718.11	(572.03)	744.39	183.62	(586.68)
(d) Employee benefits expense	2,200.16	2,242.26	2,012.70	9,699.80	4,866.90	4,945.85	4,525.09	20,560.70
(e) Finance costs	680.76	526.08	551.71	2,238.14	930.15	819.11	790.12	3,345.85
(f) Depreciation and amortisation expense	321.65	263.48	273.05	1,062.79	907.31	809.70	793.84	3,259.05
(g) Other expenses	3,634.31	4,748.51	3,598.25	16,484.52	6,841.75	8,440.36	6,074.28	28,612.56
Total expenses (IV)	12,903.90	13,974.87	11,707.49	53,074.82	21,647.13	23,622.24	19,771.30	89,401.58
V Profit/(loss) before exceptional items and tax (III - IV)	2,769.44	3,581.81	4,006.52	14,729.99	1,598.35	2,403.07	3,267.03	11,334.47
VI Exceptional items (Refer note 5)	-	-	-	(3,451.85)	-	-	-	(1,671.82)
VII Profit/(loss) before tax (V - VI)	2,769.44	3,581.81	4,006.52	18,181.84	1,598.35	2,403.07	3,267.03	13,006.29
VIII Tax expense :								
Current tax	604.77	848.44	761.55	3,834.95	959.62	874.25	1,116.28	4,765.42
Deferred tax	(113.76)	(79.51)	(105.20)	(536.14)	(454.08)	(87.80)	(179.15)	(1,009.06)
IX Profit/(loss) for the period from continuing operations (VII - VIII)	2,278.43	2,812.88	3,350.17	14,883.03	1,092.81	1,616.62	2,329.90	9,249.93
X Profit/(loss) before tax from discontinuing operations	-	-	947.07	2,028.34	-	-	-	-
XI Tax expense of discontinuing operations :								
Current tax	-	-	308.53	650.29	-	-	-	-
Deferred tax	-	-	14.80	39.96	-	-	-	-
XII Profit/(loss) for the period from discontinuing operations (X - XI)	-	-	623.74	1,338.09	-	-	-	-
XIII Profit/(loss) for the period for continuing and discontinuing operations (IX + XII)	2,278.43	2,812.88	3,973.91	16,221.12	1,092.81	1,616.62	2,329.90	9,249.93
XIV Other comprehensive income								
A (i) Items that will not be reclassified to profit or loss	18.03	(13.42)	25.10	(54.38)	(38.25)	(274.54)	28.10	(259.39)
(ii) Income tax relating to items that will not be reclassified to profit or loss	(5.57)	4.69	(8.77)	19.00	1.22	38.78	(9.16)	45.80
B (i) Items that will be reclassified to profit or loss	-	-	-	-	412.10	(951.38)	(2,725.02)	(3,710.57)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	24.99	(300.25)	-	(229.50)
XV Total comprehensive income	2,290.89	2,804.15	3,990.24	16,185.74	1,492.87	129.23	(376.18)	5,096.27
XVI Total comprehensive income attributable to:								
- Non-controlling interests	-	-	-	-	0.28	0.10	(0.04)	0.11
- Owners of the Company	2,290.89	2,804.15	3,990.24	16,185.74	1,492.59	129.13	(376.14)	5,096.16
XVII Other equity	-	-	-	119,138.72	-	-	-	55,769.67
XVIII Earning per share (EPS) (for continuing operations)								
(of Re 1/- each) (not annualised) *								
Basic EPS (in Rupees)	8.07	9.97	11.87	52.75	3.87	5.73	8.26	32.78
Diluted EPS (in Rupees)	8.07	9.97	11.87	52.74	3.87	5.73	8.26	32.78
XIX Earning per share (EPS) (for discontinuing operations)								
(of Re 1/- each) (not annualised) *								
Basic EPS (in Rupees)	-	-	2.21	4.74	-	-	-	-
Diluted EPS (in Rupees)	-	-	2.21	4.74	-	-	-	-
XX Earning per share (EPS) (for continuing and discontinuing operations)								
(of Re 1/- each) (not annualised) *								
Basic EPS (in Rupees)	8.07	9.97	14.08	57.49	3.87	5.73	8.26	32.78
Diluted EPS (in Rupees)	8.07	9.97	14.08	57.49	3.87	5.73	8.26	32.78

* except for the year ended 31 March 2019



Glenmark Pharmaceuticals Ltd.

Glenmark House, B-1 Sawant Marg, Andheri (E), Mumbai - 400 099, India

91 22 4018 9986 : 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com